Status:
TERMINATED
Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Atrial Fibrillation
Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine the long term safety and efficacy of BIBR 1048 in patients with chronic atrial fibrilla tion, with or without concomitant chronic treatment with acetylsalicylic acid (ASA).
Eligibility Criteria
Inclusion
- Inclusion criteria Diagnosis and main criteria for inclusion: Paroxysmal, persistent, or permanent (chronic) non-rheumatic atrial fibrillation with a history of coronary artery disease (CAD)
- previous treatment with BIBR 1048 in PETRO (trial 1160.20- NCT01227629) and no premature discontinuation of therapy
- paroxysmal, persistent, or permanent (chronic) non-rheumatic atrial fibrillation, documented by electrocardiogram (ECG) at least twice prior to enrollment in PETRO
- concomitant coronary artery disease -an additional risk factor for stroke (one or more of the following conditions/events): hypertension, diabetes mellitus (DM), congestive heart failure (CHF) or Left ventricular dysfunction (LVD), previous ischemic stroke or transient ischemic attack) TIA, or age greater than 75 years. -age \>= 18 years
- written, informed consent
- Exclusion criteria
Exclusion
- Valvular heart disease conferring significantly increased risk of thromboembolic events (e.g. clinically significant mitral stenosis or prosthetic valves). planned cardioversion while patients are in the study.
- contraindication to anticoagulant therapy (previous intracranial hemorrhage, gastro-intestinal (GI) hemorrhage within previous 3 months, previous severe hemorrhage with warfarin at therapeutic international normalized ratio (INR), regular use of non-steroidal anti-inflammatory drugs, hemorrhagic diathesis) major bleeding within the last 6 months (other than GI hemorrhage).
- severe renal impairment (estimated glomerular filtration rate \[GFR\] \<= 30 mL/min). uncontrolled hypertension (systolic blood pressure \[SBP\] \> 180 mm Hg and/or diastolic blood pressure \[DBP\] \> 100 mmHg).
- Women who are pregnant or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study (note: a negative pregnancy test must be obtained for any woman of childbearing potential prior to entry into the study).
- Patients who have received an investigational drug other than BIBR 1048 within the last 30 days.
- Patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration. Another indication for anticoagulant treatment (eg, deep vein thrombosis or pulmonary embolus). Clinically significant anemia (note: patients with mild-moderate anemia should only be enrolled after the possibility of a GI bleeding source has been evaluated, the etiology of the anemia identified, and appropriate action taken). Patients suffering from thrombocytopenia (platelets \< 100,000/uL). Any other condition which, in the discretion of the investigator, would not allow safe participation in the study.
- Continuing or planned concomitant treatment with antiplatelet agents other than acetylsalicylic acid (ASA).
- Recent malignancy or radiation therapy (\<= 6 months).
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
361 Patients enrolled
Trial Details
Trial ID
NCT00157248
Start Date
December 1 2003
Last Update
May 19 2014
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
1160.42.10003 Boehringer Ingelheim Investigational Site
La Mesa, California, United States
2
1160.42.10006 Boehringer Ingelheim Investigational Site
Pensacola, Florida, United States
3
1160.42.10004 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida, United States
4
1160.42.10002 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States